

CITATION REPORT

List of articles citing

Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses

DOI: 10.1016/s0022-5347(05)64442-4
Journal of Urology, 2002, 168, 1332-1336.

Source: <https://exaly.com/paper-pdf/34118723/citation-report.pdf>


Version: 2022-10-02

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
461	Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. 2002 , 4, H7-H12		13
460	Current oral treatments for erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 1613-29	3.8	6
459	What Do Patients Expect from Erectile Dysfunction Therapy?. 2002 , 1, 4-11		14
458	Oral Agents: First-Line Therapy for Erectile Dysfunction. 2002 , 1, 12-18		22
457	Restoring a Normal Sexual Response: The Ultimate Goal of Erectile Dysfunction Therapy. 2002 , 1, 19-24		3
456	Tadalafil Phase 3 Experience. 2002 , 1, 25-30		
455	Tadalafil in the treatment of erectile dysfunction. 2003 , 4, 472-8		13
454	[Drug therapy of erectile dysfunction--the current status]. 2003 , 42, 1322-9		2
453	Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. 2003 , 92, 19M-25M		85
452	Tadalafil: a new treatment for erectile dysfunction. 2003 , 91, 466-8		5
451	Novel agents for sexual dysfunction. 2003 , 92, 534-8		7
450	Pharmacoepidemiology and drug safety. 2003 , 12, 253-68		
449	Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy. <i>International Journal of Impotence Research</i> , 2003 , 15, 383-4	2.1	11
448	Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. <i>International Journal of Impotence Research</i> , 2003 , 15 Suppl 5, S13-9	2.1	14
447	Disfunciã erãtil. 2003 , 8, 6092-6100		
446	Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. <i>Journal of Urology</i> , 2003 , 169, 1999-2007	1.5	81
445	Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. <i>Journal of Urology</i> , 2003 , 170, 887-91	1.5	105

444	Time course of the interaction between tadalafil and nitrates. 2003 , 42, 1855-60		130
443	Tadalafil. 2003 , 63, 2203-12; discussion 2213-4		49
442	Novel PDE5 inhibitors for the treatment of male erectile dysfunction. 2003 , 7, 456-61		13
441	Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction. 2003 , 28, 291-7		3
440	Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. 2003 , 62, 121-5; discussion 125-6		242
439	A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. 2003 , 25, 2709-23		81
438	Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. 2003 , 25, 2724-37		65
437	Current and future trends in the oral pharmacotherapy of male erectile dysfunction. 2003 , 12, 1521-33		10
436	New achievements and pharmacotherapeutic approaches to impotence in the elderly. 2003 , 15, 222-33		1
435	New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction. 2003 , 123, 79-80		
434	Review of tadalafil in the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 2049-56	3.8	13
433	Cialis (tadalafil): a new treatment for erectile dysfunction. 2003 , 64, 589-92		2
432	Phosphodiesterase 5 inhibitors in male sexual dysfunction. 2003 , 13, 405-10		10
431	Current World Literature. 2003 , 13, 423-429		
430	Oral agents for erectile dysfunction. 2003 , 64, 292-5		
429	Rosiglitazone for Treatment of HIV Lipodystrophy. 2004 , 141, 739		
428	To Butterfly or To Needle: The Specimen Testing Question. 2004 , 141, W-140		1
427	Erectile Dysfunction in the Elderly: Epidemiology, Etiology, and Approaches to Treatment. 2004 , 241-254		1

426	. 2004 ,	1
425	Low-Carbohydrate Diets. 2004 , 141, 738	
424	Residents' work hours. 2004 , 141, 740; author reply 742	
423	Tadalafil in primary pulmonary arterial hypertension. 2004 , 141, 743-4	40
422	Sexual Dysfunction and Renal Disease. 143-157	1
421	Sexual dysfunction screening: the advantages of a culturally sensitive joint assessment clinic. 2004 , 19, 179-189	4
420	Review: PDE-5 inhibitors  summary. 2004 , 4, 383-386	3
419	From Informed Consent through Database Lock: An Interactive Clinical Trial Conducted Using the Internet. 2004 , 38, 239-251	6
418	A 66-year-old man with sexual dysfunction. 2004 , 291, 2994-3003	17
417	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246	
416	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. 2004 , 17, 239-250	1
415	Erectile dysfunction: management update. 2004 , 170, 1429-37	68
414	Emerging pharmacologic approaches for the treatment of lower urinary tract disorders. 2004 , 308, 797-804	24
413	Treatment of erectile dysfunction. 2004 , 15, 215-21	7
412	The efficacy and safety of tadalafil: an update. 2004 , 93, 1276-81	153
411	Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. 2004 , 94, 1301-9	60
410	Challenges in the assessment of erectile dysfunction and treatment with oral therapies: review with case examples. 2004 , 16, 428-40	
409	NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. <i>International Journal of Impotence Research</i> , 2004 , 16, 195-200	2.1 20

408	Document for the general public. Spanish consensus panel on erectile dysfunction. <i>International Journal of Impotence Research</i> , 2004 , 16 Suppl 2, S7-9	2.1	
407	Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility. <i>International Journal of Impotence Research</i> , 2004 , 16, 459-69	2.1	49
406	Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. 2004 , 1, 292-300		92
405	Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. 2004 , 1, 322-36		29
404	Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. 2004 , 1, 161-7		38
403	Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. 2004 , 1, 193-200		27
402	Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. 2004 , 1, 201-8		20
401	Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. 2004 , 45, 339-44; discussion 344-5		98
400	A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. 2004 , 45, 499-507; discussion 507-9		73
399	Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. 2004 , 46, 362-9; discussion 369		45
398	The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. <i>Archives of Sexual Behavior</i> , 2004 , 33, 19-30	3.4	72
397	Therapy of ED: PDE-5 Inhibitors. 2004 , 23, 135-41		24
396	Population dose-response model for tadalafil in the treatment of male erectile dysfunction. 2004 , 21, 1463-70		10
395	Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. 2004 , 27, 114-19		49
394	Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. 2004 , 47, 1914-23		124
393	Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. 2004 , 5, 467-71		37
392	The impact of erectile dysfunction and its treatment with phosphodiesterase type-5 (PDE5) inhibitors in patients with diabetes. 2004 , 21, 225-230		1
391	[The influence of technical products on sexual activity and gender relations: oral contraceptive, condom, oral treatments of sexual disorders]. 2004 , 52, 377-87		15

390	Erectile dysfunction: etiology, evaluation, and treatment options. 2004 , 88, 387-416, xi		8
389	Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis. 2004 , 2, 56-56		
388	Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. <i>Journal of Urology</i> , 2004 , 172, 1935-40	1.5	129
387	The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction. <i>Journal of Urology</i> , 2004 , 172, 652-7	1.5	33
386	Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. <i>Journal of Urology</i> , 2004 , 172, 1036-41	1.5	172
385	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. 2004 , 44, 1488-96		83
384	New phosphodiesterase inhibitors in the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2241-9	3.8	10
383	Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection. 2004 , 64, 1533-45		15
382	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88		62
381	Sildenafil. 2004 ,		
380	Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy. 2004 , 2, 75-83		12
379	Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis. 2004 , 2, 56-63		17
378	Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction. 2004 , 64, 783-8		25
377	Therapeutic interventions targeting the nitric oxide system: current and potential uses in obstetrics, bone disease and erectile dysfunction. 2004 , 74, 1701-21		5
376	Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. 2004 , 25, 830-6		111
375	Erectile dysfunction: evaluation and new treatment options. 2004 , 66, 664-71		28
374	Current World Literature. 2004 , 14, 395-407		
373	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionA randomized prospective study. 2004 , 44, 1488-1496		252

372	Understanding erectile dysfunction medication preference studies. 2004 , 14, 367-73		29
371	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. 2004 , 1, 185-196		
370	Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. 2005 , 77, 63-75		73
369	In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. 2005 , 96, 164-8		16
368	Phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 96, 257-80		148
367	Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. 2005 , 96, 857-63		12
366	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. 2005 , 96, 1323-32		77
365	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. 2005 , 60, 459-68		18
364	Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial. <i>International Journal of Impotence Research</i> , 2005 , 17, 76-9	2.1	6
363	Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. <i>International Journal of Impotence Research</i> , 2005 , 17, 431-6	2.1	26
362	Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. <i>International Journal of Impotence Research</i> , 2005 , 17, 450-4	2.1	21
361	From aspiration to achievement: assessment and noninvasive treatment of erectile dysfunction in aging men. 2005 , 53, 119-30		14
360	A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. 2005 , 59, 143-9		14
359	Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. 2005 , 47, 214-20; discussion 220-2		184
358	An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. 2005 , 47, 846-54; discussion 854		42
357	Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments?. 2005 , 96, 13M-18M		63
356	The efficacy and safety of PDE5 inhibitors. 2005 , 7, 47-56		23
355	The therapeutic dilemma: how to use tadalafil. 2005 , 28 Suppl 2, 74-80		33

354	Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction. 2005 , 2, 461-8	16
353	The efficacy of tadalafil in clinical populations. 2005 , 2, 517-31	55
352	Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. 2005 , 2, 685-98	21
351	Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries. 2005 , 2, 668-74	10
350	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 2, 848-55	28
349	Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. 2005 , 2, 415-25; discussion 425-7	76
348	Nitric oxide and penile erectile function. 2005 , 106, 233-66	156
347	Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. 2005 , 23, 385-92	37
346	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. 2005 , 23, 374-84	26
345	Erectile dysfunction: interrelationship with the metabolic syndrome. 2005 , 5, 64-9	31
344	Erectile dysfunction in the aging male. 2005 , 2, 13-16	
343	Hypogonadism in the man with erectile dysfunction: what to look for and when to treat. 2005 , 6, 476-81	16
342	Tadalafil: a clinical update. <i>Aging Health</i> , 2005 , 1, 203-214	2
341	Is Diabetic Erectile Dysfunction More Difficult to Treat?. 2005 , 221-236	
340	Clinical monograph for drug formulary review: erectile dysfunction agents. 2005 , 11, 151-71	33
339	Recurrent epistaxis after treatment with tadalafil (Cialis). 2005 , 125, 334-5	8
338	Tadalafil. 2005 , 85-107	
337	[Management of erectile dysfunction in the cardiac patient]. 2005 , 130, 2899-903	2

336	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 2, 239-47		40
335	Sildenafil Citrate, the Classic PDE5 Inhibitor. 2005 , 65-83		4
334	Integrating medication, realistic expectations, and therapeutic interventions in the treatment of male sexual dysfunction. 2005 , 31, 319-28		47
333	The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. 2005 , 45, 987-1003		118
332	Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: integrated analysis of randomized, placebo controlled trials. <i>Journal of Urology</i> , 2005 , 174, 1356-9	1.5	13
331	Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 ,		
330	A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. 2005 , 19, 655-71		55
329	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 75-84	3.8	43
328	Phosphodiesterase 5 inhibitors for erectile dysfunction. 2005 , 39, 1286-95		60
327	[Erectile dysfunction drugs and women]. 2005 , 33, 590-3		1
326	Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. 2005 , 65, 353-9		53
325	The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials. 2005 , 21, 1701-9		14
324	Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. 2005 , 26, 310-8		47
323	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. 2005 , 65, 1621-50		128
322	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. 2005 , 4, 531-40		16
321	The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. 2005 , 46, 678-87		27
320	Nitric oxide-based therapy for erectile disorders. 2005 , 2, 25-30		2
319	Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part I). 2005 , 2, 87-94		2

318	Frequently asked questions about tadalafil for treating men with erectile dysfunction. 2005 , 2, 141-157	1
317	PDE-5 inhibitors: current status and future trends. 2005 , 32, 511-25, viii	24
316	Safety and tolerability of oral erectile dysfunction treatments in the elderly. 2005 , 22, 323-38	5
315	Aging in the Hypothalamic-Pituitary-Testicular Axis. 2006 , 2697-2728	5
314	[Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study]. 2006 , 30, 67-79	5
313	Combined angiotensin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. 2006 , 13, 705-15	71
312	The Role of Erection Hardness in Determining Erectile Dysfunction (ED) Treatment Outcome. 2006 , 5, 767-772	5
311	Psychological, Social, and Behavioural Benefits for Men Following Effective Erectile Dysfunction (ED) Treatment: Men Who Enjoy Better Sex Experience Improved Psychological Well-Being. 2006 , 5, 773-778	6
310	Partner Satisfaction and Successful Treatment Outcomes for Men with Erectile Dysfunction (ED). 2006 , 5, 779-785	8
309	Erectile dysfunction. <i>Journal of Urology</i> , 2006 , 175, S25-31	1.5 41
308	[Efficacy and safety of two dosing regimens with Tadalafil in Spanish men with erectile dysfunction: results from the SURE study in 14 European countries]. 2006 , 30, 791-800	1
307	An overview of the diagnosis and treatment of erectile dysfunction. 2006 , 66, 2339-55	17
306	Oral Therapy for Erectile Dysfunction. 2006 , 271-286	
305	Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. 2006 , 114, 1807-10	108
304	The role of nitric oxide in erectile dysfunction: implications for medical therapy. 2006 , 8, 53-62	108
303	Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance?. 2006 , 3, 342-349	5
302	Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. 2006 , 108, 429-31	38
301	Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. 2006 , 67, 225-31	7

300	Effect of Epimedium brevicornum Maxim extract on elicitation of penile erection in the rat. 2006 , 67, 631-5		17
299	An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. 2006 , 68, 386-91		45
298	Through the eyes of women: the partners' perspective on tadalafil. 2006 , 68, 631-5		31
297	Erectile Dysfunction in Diabetes: An Endothelial Disorder. 2006 , 165-178		1
296	. 2006 ,		21
295	Male Sexual Function. 2006 , 1173-1194		1
294	. 2006 ,		
293	Oral Pharmacotherapy of Erectile Dysfunction. 75-93		5
292	Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. 2006 , 17, 493-9		8
291	Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression. 2006 , 11, 31-7		14
290	Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. 2006 , 98, 623-9		22
289	Tadalafil associated with typical migraine aura without headache. 2006 , 26, 1344-6		10
288	Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. 2006 , 8, 685-92		22
287	Tadalafil pharmacokinetics in healthy subjects. 2006 , 61, 280-8		184
286	Can self-administered questionnaires supplant objective testing of erectile function? A comparison between the International Index Of Erectile Function and objective studies. <i>International Journal of Impotence Research</i> , 2006 , 18, 126-9	2.1	14
285	A 15-item short form of the psychological and interpersonal relationship scales. <i>International Journal of Impotence Research</i> , 2006 , 18, 82-8	2.1	26
284	Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. <i>International Journal of Impotence Research</i> , 2006 , 18, 229-35	2.1	49
283	Preference studies are of value to the field of sexual medicine: Con. 2006 , 3, 9-12		

282	Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design. 2006 , 3, 492-503		23
281	Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction. 2006 , 3, 504-11		5
280	Treatment-seeking behavior of erectile dysfunction patients in Europe: Results of the Erectile Dysfunction Observational Study. 2006 , 3, 530-40		32
279	Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study. 2006 , 3, 716-722		33
278	Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. 2006 , 3, 668-675		14
277	Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. 2006 , 3, 901-909		45
276	Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens. 2006 , 3, 1050-1058		8
275	EAU Guidelines on erectile dysfunction: an update. 2006 , 49, 806-15		199
274	Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. 2006 , 50, 351-9		133
273	Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. 2006 , 50, 1194-207; discussion 1207		73
272	Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. 2006 , 1118, 192-8		112
271	Counseling patients about sexual issues. 2006 , 26, 1608-15		6
270	Cardiovascular effects of phosphodiesterase 5 inhibitors. 2006 , 12, 3485-94		43
269	Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. 2006 , 12, 3467-84		45
268	Post-marketing surveillance study of the efficacy and safety of vardenafil among patients with erectile dysfunction in primary care. <i>International Journal of Impotence Research</i> , 2007 , 19, 393-7	2.1	11
267	Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS). <i>International Journal of Impotence Research</i> , 2007 , 19, 76-83	2.1	6
266	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. <i>International Journal of Impotence Research</i> , 2007 , 19, 139-48	2.1	45
265	Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. 2007 , 64, 1584-92		50

264	Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. <i>International Journal of Impotence Research</i> , 2007 , 19, 95-103	2.1	90
263	Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. 2007 , 47, 1303-10		15
262	Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. 2007 , 334, 466-80		14
261	Phosphodiesterase type 5 inhibitors: state of the therapeutic class. 2007 , 34, 507-15, vi		22
260	A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction. 2007 , 4, 745-752		6
259	The Good-Enough Sex model for couple sexual satisfaction. 2007 , 22, 351-362		94
258	Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 965-74	3.8	12
257	Treatment options for erectile dysfunction. 2007 , 36, 465-79		31
256	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , 2007 , 19, 281-95	2.1	32
255	Interventions for sexual dysfunction following treatments for cancer. 2007 , CD005540		47
254	An Alternative dosing Regimen with Tadalafil 3 Times/Week in the Treatment of Erectile Dysfunction: Italian Data from the SURE Study. 2007 , 74, 30-36		
253	Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors. 2007 , 26, 378-90		37
252	The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. 2007 , 99, 376-82		21
251	Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. 2007 , 63, 24-35		46
250	Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. 2007 , 61, 1850-62		24
249	Evaluation of an alternative dosing regimen with tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy. 2007 , 9, 395-402		6
248	Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). 2007 , 51, 541-50; discussion 550		42
247	Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. 2007 , 4, 166-175		35

246	[Novel indications for phosphodiesterase type 5 inhibitors]. 2007 , 102, 617-30	4
245	Integrating Sex Therapy Interventions with Couple Therapy. 2008 , 38, 139-149	25
244	[The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]. 2008 , 47, 1582-7	3
243	Management of erectile dysfunction in diabetes: an update for 2008. 2008 , 8, 437-43	8
242	Phosphodiesterase 5 inhibition in essential hypertension. 2008 , 10, 52-7	27
241	Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. 2006 , 60, 812-9	8
240	Global experiences with vardenafil in men with erectile dysfunction and underlying conditions. 2008 , 62, 1594-603	6
239	Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. 2008 , 13, 916-8	29
238	JSSM Guidelines for erectile dysfunction. <i>International Journal of Urology</i> , 2008 , 15, 564-76	2.2 6
237	Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. 2008 , 25, 138-46	97
236	Effects of written information material on help-seeking behavior in patients with erectile dysfunction: a longitudinal study. 2008 , 5, 436-47	14
235	Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States. 2008 , 5, 716-25	19
234	The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. 2008 , 5, 946-953	56
233	British Society for Sexual Medicine guidelines on the management of erectile dysfunction. 2008 , 5, 1841-65	97
232	Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. 2008 , 5, 1708-19	10
231	Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses. 2008 , 5, 1965-76	12
230	Relationship factors in the development and maintenance of ED: implications for treatment effectiveness. 2008 , 5, 1795-804	21
229	Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. 2008 , 5, 2170-8	101

228	Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. 2008 , 5, 2672-80	56
227	Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. 2009 , 6, 232-42	1
226	Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. 2008 , 48, 610-8	81
225	Problems in understanding the Turkish translation of the international index of erectile function. 2008 , 29, 369-73	16
224	The cardiovascular safety of tadalafil. 2008 , 7, 43-52	7
223	Sexual and marital aspects of old age: an update. 2008 , 23, 161-169	4
222	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. 2008 , 5, 355-365	2
221	[Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)]. 2008 , 131, 469-77	1
220	Tadalafil in the treatment of erectile dysfunction. 2008 , 4, 1315-30	51
219	Endocrinology. 2008 , 127-162	1
218	Tadalafil versus sildenafil citrate in the treatment of ED: Italian patients' preferences and explanatory notes. 2008 , 75, 24-31	1
217	Update on the Use of Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction. 2009 , 2, 113-121	1
216	Erection, emission, and ejaculation:.. 132-152	
215	Effect of erectile dysfunction medications on coexisting sexual dysfunctions in couples: Partners' Preference Study. 2009 , 24, 316-332	1
214	Psychiatric Genetics: Applications in Clinical Practice edited by Jordan W. Smoller, M.D., Sc.D., Beth Rosen Sheidley, M.S., C.G.C., and Ming T. Tsuang, M.D., Ph.D., D.Sc. Arlington, Va., American Psychiatric Publishing, 2008, 337 pp., \$60.00.. 2009 , 166, 377-379	
213	Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. 2009 , 6, 520-34	35
212	Aspects of Sexual Satisfaction in Men with Erectile Dysfunction: A Factor Analytic and Logistic Regression Approach. 2009 , 6, 232-242	6
211	Correlation of degree of penile curvature between patient estimates and objective measures among men with Peyronie's disease. 2009 , 6, 862-5	31

210	Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. 2009 , 6, 2039-48	48
209	Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial. 2009 , 6, 3469-77	25
208	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. 2009 , 48, 1318, 1320-9	5
207	Tadalafil. 2009 , 26, 124-125	
206	Treatment of erectile dysfunction reduces psychological distress. 2009 , 32, 74-80	18
205	Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis. 2009 , 11, 423-33	7
204	Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. 2009 , 63, 27-34	17
203	The burden and extent of comorbid conditions in patients with erectile dysfunction. 2009 , 63, 1205-13	42
202	Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. 2010 , 64, 240-55	108
201	Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. 2009 , 32, 1-18	55
200	Cardiovascular Endocrinology. 2009 ,	2
199	Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions. 2009 , 84, 139-148	72
198	Remembering Home: Rediscovering the Self in Dementia by Habib Chaudhury. Baltimore, Johns Hopkins University Press, 2008, 144 pp., \$40.00.. 2009 , 166, 376-377	
197	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. 2009 , 15, 3486-95	16
196	Conservative treatment of erectile dysfunction. 2010 , 380-386	
195	The effect of tadalafil on anastomotic healing in ischemic small intestine in rats. 2010 , 40, 555-60	5
194	Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors. 2010 , 7, 203-15	24
193	Standards for clinical trials in male sexual dysfunctions. 2010 , 7, 414-44	32

192	Considerations for diagnostic criteria for erectile dysfunction in DSM V. 2010 , 7, 654-60		27
191	Cardiovascular aspects of sexual medicine. 2010 , 7, 1608-26		76
190	Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. 2010 , 7, 2842-50		22
189	Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. 2010 , 7, 2851-9		22
188	Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. 2010 , 7, 3635-46		34
187	In sight into tadalafil - block copolymer binary solid dispersion: Mechanistic investigation of dissolution enhancement. 2010 , 402, 78-88		46
186	Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study. 2010 , 51, 647-52		13
185	The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2010 , 6, 273-80	4.2	21
184	Key features for designing phosphodiesterase-5 inhibitors. 2010 , 28, 309-21		33
183	Clinical Andrology. 2010 ,		1
182	ACceptance of therapy in vardenafil-treated patients with Erectile dysfunction (ACTIVE): A noninterventional study in Germany. <i>International Journal of Impotence Research</i> , 2010 , 22, 61-7	2.1	2
181	Treatment of Erectile Dysfunction. 341-354		
180	Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database. 2010 , 27, 627-40		54
179	Tadalafil. 2011 , 36, 287-329		12
178	Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. 2011 , 97, 1876-81		54
177	Newer phosphodiesterase inhibitors: comparison with established agents. 2011 , 38, 155-63		9
176	Contemporary Treatment of Erectile Dysfunction. 2011 ,		2
175	Efficacy and tolerability of tadalafil for treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. 2011 , 77, 1137-41		21

174	Apomorphine for the treatment of erectile dysfunction. 2011 ,		
173	Sexual evaluation and treatment of ageing males with haemophilia. 2011 , 17, 875-83		9
172	Patients' preference in the treatment of erectile dysfunction: a critical review of the literature. <i>International Journal of Impotence Research</i> , 2011 , 23, 1-8	2.1	16
171	Stopwatch-assessed duration of erection: a new measure of the efficacy of erectile dysfunction treatments. <i>International Journal of Impotence Research</i> , 2011 , 23, 9-16	2.1	5
170	Poly(ADP-Ribose) polymerase inhibition improves erectile function in diabetic rats. 2011 , 8, 1002-14		15
169	Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. 2011 , 8, 851-64		9
168	Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. 2011 , 8, 2894-903		54
167	Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. 2011 , 60, 1010-6		234
166	Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction. 2011 , 12, 455-9		
165	Tadalafil inclusion in microporous silica as effective dissolution enhancer: optimization of loading procedure and molecular state characterization. 2011 , 100, 1805-18		32
164	Metabolic syndrome and sexual dysfunction. 2011 , 21, 514-8		25
163	Erectile dysfunction: A review and herbs used for its treatment. 2012 , 6, 109		11
162	Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. <i>Journal of Urology</i> , 2012 , 187, 1769-75	1.5	168
161	Sexual function in men with metabolic syndrome. 2012 , 39, 53-62		12
160	Analysis of the therapeutic effect of tadalafil on male ED after transurethral resection of prostate. <i>International Journal of Impotence Research</i> , 2012 , 24, 147-9	2.1	2
159	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1481-94	3.8	15
158	Combined tadalafil and α -blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study. 2012 , 33, 397-403		14
157	Gene therapy with an erythropoietin enhancer-mediated, hypoxia-inducible gene expression system in the corpus cavernosum of mice with high-cholesterol diet-induced erectile dysfunction. 2012 , 33, 845-53		7

156	Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis. 2012 , 38, 112-22	4
155	Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. 2012 , 58, 3-14	53
154	Protective effects of <i>Launaea procumbens</i> on rat testis damage by CCl ₄ . 2012 , 11, 103	25
153	Therapeutic angiogenesis as a potential future treatment strategy for erectile dysfunction. 2012 , 30, 93-8	3
152	Treatment Effectiveness and Side Effects: A Model of Physician Learning. 2012 ,	
151	Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile. 2012 , 9, 169-79	13
150	Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil. 2012 , 109, 1060-7	13
149	Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. 2012 , 110, 1801-6	34
148	A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. 2013 , 111, 137-47	21
147	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. 2013 , 15, 475-83	41
146	Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. 2013 , 11, 222-9	24
145	PDE5 inhibitors: considerations for preference and long-term adherence. 2013 , 67, 768-80	69
144	SOP conservative (medical and mechanical) treatment of erectile dysfunction. 2013 , 10, 130-71	112
143	Erectile function, erection hardness and tolerability in men treated with sildenafil 100 mg vs. 50 mg for erectile dysfunction. 2013 , 67, 1034-9	6
142	[Drugs for sexual medicine]. 2013 , 23, 1299-311	1
141	Historical revolutions in sex therapy: a critical examination of men's sexual dysfunctions and their treatment. 2013 , 39, 21-39	12
140	Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. 2013 , 10, 1592-602	25
139	Primer of Geriatric Urology. 2013 ,	

138	Erectile dysfunction - an update of current practice and future strategies. 2013 , 6, 210-219		2
137	Treatment Effectiveness and Side Effects: A Model of Physician Learning. 2013 , 59, 1309-1325		37
136	A guanidinylated bio-reducible polymer as a novel gene carrier to the corpus cavernosum of mice with high-cholesterol diet-induced erectile dysfunction. <i>Andrology</i> , 2013 , 1, 216-22	4	10
135	Nonresponders, partial responders, and complete responders to PDE5 inhibitors therapy according to IIEF criteria: validation of an anchor-based treatment responder classification. 2013 , 10, 3029-37		6
134	High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction. 2013 , 10, 2774-81		19
133	Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. 2013 , 31, 83-102		19
132	Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. 2014 , 32, 18-27		7
131	Sexual Dysfunction and Couple Dysfunction. 2014 ,		
130	Management of erectile dysfunction in hypertension: Tips and tricks. 2014 , 6, 908-15		34
129	Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. <i>International Journal of Impotence Research</i> , 2014 , 26, 223-9	2.1	11
128	A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. 2014 , 11, 820-30		12
127	Efficient Cross-Coupling of Dioxazaborocanes with β -Phosphate Enamides. 2014 , 2014, 7889-7894		4
126	Chinese herb formulae for treatment of erectile dysfunction: a systematic review of randomised controlled clinical trials. <i>Andrologia</i> , 2014 , 46, 201-23	2.3	5
125	A broad-spectrum approach to daily tadalafil: making the big picture even bigger. 2014 , 65, 465-6		
124	Sexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: an Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaire. <i>International Journal of Urology</i> , 2014 , 21, 821-5	2.2	8
123	Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. 2014 , 11, 231-41		26
122	Erectile dysfunction. 2014 , 44, 18-26		44
121	Erectile dysfunction. 2014 , 348, g129		30

120	A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. 2014 , 11, 187-96	48
119	Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study. 2014 , 68, 1087-99	15
118	Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. 2014 , 83, 1326-33	14
117	Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse. 2015 , 5, 9222	12
116	Once-a-day Tadalafil administration improves the spermogram parameters in fertile patients. 2015 , 87, 210-3	11
115	A comprehensive review of erectile dysfunction in men with diabetes. 2015 , 123, 141-58	44
114	Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. 2015 , 15, 111	13
113	Role of sGC-dependent NO signalling and myocardial infarction risk. 2015 , 93, 383-94	22
112	Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily. 2015 , 12, 720-7	8
111	Guía de disfunción eréctil. Sociedad Colombiana de Urología. 2015 , 24, 185.e1-185.e22	2
110	Tadalafil-loaded nanostructured lipid carriers using permeation enhancers. 2015 , 495, 701-9	36
109	Sexual challenges with aging: integrating the GES approach in an elderly couple. 2015 , 41, 72-82	5
108	Nanovesicular carrier-mediated transdermal delivery of tadalafil: i-formulation and physicochemical characterization. 2015 , 41, 714-21	14
107	Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine. 2016 , 24, 90	
106	Sexual Dysfunction in Men and Women. 2016 , 785-830	1
105	The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction. 2016 , 5, 181-6	6
104	PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. 2016 , 52, 295-302	24
103	Drug therapy for erectile dysfunction. 2016 , 172-193	

102 Sexual Function in Men and Women with Diabetes. **2016**, 716-730

101	The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. <i>Journal of Urology</i> , 2016 , 196, 715-20	1.5	7
100	The quest for an increased genital size drives sex stimulant abuse among male subjects in Calabar, Cross River State, Nigeria. 2016 , 5, 311-316		1
99	Primer of Geriatric Urology. 2016 ,		
98	Geriatric Sexuality. 2016 , 163-227		
97	Contemporary Treatment of Erectile Dysfunction. <i>Contemporary Endocrinology</i> , 2016 ,	0.3	2
96	Avanafil for the treatment of erectile dysfunction. 2016 , 9, 1163-70		9
95	Erectile dysfunction patients are more satisfied with penile prosthesis implantation compared with tadalafil and intracavernosal injection treatments. <i>Andrology</i> , 2016 , 4, 952-6	4	18
94	Diagnostik und medikamentöse Therapie der erektilen Dysfunktion. 2016 , 1513-1521		
93	Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience. 2016 , 8, 249-256		7
92	Avanafil - a further step to tailoring patient needs and expectations. 2016 , 9, 1171-81		5
91	The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. 2016 , 15, 141-52		34
90	The role of the sexual partner in managing erectile dysfunction. 2016 , 13, 168-77		31
89	The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. 2016 , 15, 237-47		35
88	The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis. 2016 , 38, 357-61		2
87	Transdermal delivery of tadalafil using a novel formulation. 2016 , 23, 1571-7		8
86	Dissolution enhancement of tadalafil by liquisolid technique. 2017 , 22, 77-89		14
85	Low-energy Shock Wave Therapy-A Novel Treatment Option for Erectile Dysfunction in Men With Cardiovascular Disease. 2017 , 109, 19-26		7

84	[Erectile dysfunction : Current diagnostics and treatment]. 2017 , 56, 519-529	9
83	Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient. 2017 , 19, 89	15
82	Diversity-Oriented Syntheses by Combining CuAAC and Stereoselective INCIC Reactions with Peptides. 2017 , 23, 13869-13874	7
81	ERECTILE DYSFUNCTION AND ITS PHARMACOLOGY: AN OVERVIEW. 2017 , 10, 17	1
80	Sexual Dysfunction: Behavioral, Medical, and Surgical Treatment. 2018 , 102, 349-360	0
79	The nitric oxide-guanylate cyclase pathway and glaucoma. 2018 , 77, 75-87	27
78	British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017. 2018 , 15, 430-457	61
77	Resumen de la Guía de Práctica Clínica de Disfunción Eréctil [Sociedad Colombiana de Urología]. 2018 , 27, 203-213	
76	A randomized double-blind, placebo-controlled, cross-over trial assessing the effect of tadalafil (Cialis) on the cardiovascular response in men with complete spinal cord injury above the sixth thoracic level: A Pilot Study. 2018 , 4, 105	2
75	Characterization and Stability of Amorphous Tadalafil and Four Crystalline Polymorphs. 2018 , 66, 1114-1121	9
74	Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs. 2018 , 10,	7
73	Treatment Approaches to Sexual Dysfunction in Late Life. 2018 , 5, 255-274	
72	[S1-Guideline for Diagnosis and Treatment of Erectile Dysfunction]. 2019 , 87, 225-233	2
71	An update on the drug safety of treating erectile dysfunction. 2019 , 18, 965-975	5
70	Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction. 2019 , 7, 282-291	7
69	FORMULATION DEVELOPMENT OF IMMEDIATE RELEASE PELLETS OF TADALAFIL: SOLIDIFICATION APPROACH FOR NANOSUSPENSION. 2019 , 124-131	1
68	A global meta-analyses of the response of multi-taxa diversity to grazing intensity in grasslands. 2019 , 14, 114003	18
67	Efficacy and safety of combination of tadalafil and aspirin versus tadalafil or aspirin alone in patients with vascular erectile dysfunction: a comparative randomized prospective study. 2019 , 51, 1491-1499 ¹	

66	Current diagnosis and management of erectile dysfunction. 2019 , 210, 469-476		25
65	The effect of surfactant and polymer on solution stability and solubility of tadalafil-methylparaben cocrystal. 2019 , 281, 86-92		3
64	cis-Selective synthesis of 1,3-disubstituted tetrahydro- β -carbolines from N-sulfonyl N,S-acetals. 2019 , 17, 9510-9513		1
63	Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration. 2019 , 121, 65-75		6
62	Pharmacodynamics of the agents used for the treatment of erectile dysfunction. 2019 , 15, 121-131		3
61	The Pictet-Bengler Reaction: A Powerful Strategy for the Synthesis of Heterocycles. <i>Advances in Heterocyclic Chemistry</i> , 2019 , 127, 153-226	1.8	12
60	Chinese herbal medicine combined with tadalafil for erectile dysfunction: a systematic review and meta-analysis. <i>Andrology</i> , 2020 , 8, 268-276	4	5
59	Acute pancreatitis induced by Tadalafil: a case report. <i>Clinical Journal of Gastroenterology</i> , 2020 , 13, 459-464		1
58	A prospective study of the effect of antihypertensive medications on the sexual functions of hypertensive adult male patients. <i>Future Science OA</i> , 2020 , 6, FSO479	2.6	2
57	Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review. <i>International Journal of Retina and Vitreous</i> , 2020 , 6, 38	2.8	5
56	Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis. <i>Archives of Sexual Behavior</i> , 2020 , 49, 2963-2979	3-4	3
55	The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. <i>Journal of Clinical Medicine</i> , 2020 , 9,	4-9	4
54	Effect of daily tadalafil on reported outcomes in patients with erectile dysfunction and depressive symptoms: STROBE, a case-control study. <i>Medicine (United States)</i> , 2020 , 99, e20546	1-7	1
53	Pharmacology and perspectives in erectile dysfunction in man. <i>Pharmacology & Therapeutics</i> , 2020 , 208, 107493	13-3	15
52	"Doc, if it were you, what would you do?": a survey of Men's Health specialists' personal preferences regarding treatment modalities. <i>International Journal of Impotence Research</i> , 2021 , 33, 303-310		1
51	Impact of antiangiogenic treatment on the erectile function in patients with advanced renal cell carcinoma. <i>Andrologia</i> , 2021 , 53, e13881	2-3	
50	Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 821-834	3-8	1
49	Vitamin E and ginseng combined supplement for treatment of male erectile dysfunction: A double-blind, placebo-controlled, randomized, clinical trial. <i>Advances in Integrative Medicine</i> , 2021 , 8, 44-49	1-2	2

48	Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial. <i>International Journal of Urology</i> , 2021 , 28, 432-438	2.2	1
47	Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction. <i>European Urology Focus</i> , 2021 ,	4.9	1
46	Diagnosis and management of erectile dysfunction. <i>Trends in Urology & Men's Health</i> , 2021 , 12, 12-17	0.3	1
45	Sexual dysfunctions. 2021 , 235-285		
44	Sexual Function in Men and Woman with Diabetes. 743-759		1
43	Geriatric Sexuality. 2013 , 143-200		1
42	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161		1
41	Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie's Disease. 2020 , 357-392		1
40	Sexual Dysfunction in Men and Women. 2011 , 778-816		2
39	Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 439-49	3.8	9
38	Sexual function in hypertensive patients receiving treatment. <i>Vascular Health and Risk Management</i> , 2006 , 2, 447-55	4.2	30
37	Effect of tadalafil on erectile dysfunction in male patients with diabetes mellitus. <i>Vojnosanitetski Pregled</i> , 2007 , 64, 399-404	0.1	5
36	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246		0
35	Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. <i>Korean Journal of Internal Medicine</i> , 2007 , 22, 37-9	2.5	4
34	Sexuality. 2004 , 259-298		
33	Management of Erectile Dysfunction. 2004 , 65-88		
32	Neue Arzneimittel. 2004 , 37-75		
31	Pharmacotherapy and External Devices for Erectile Dysfunction. 2004 , 87-98		

- 30 Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. **2004**, 159-181
- 29 The phosphodiesterase V inhibitor low responder study (PILRS) in patients with erectile dysfunction [A rationale for a PDE5 inhibitor combination therapy. **2004**, 169-181
- 28 Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. **2004**, 129-142
- 27 References. **2004**, 56-58
- 26 Human sexuality. **2004**, 96-108
- 25 Tadalafil. **2005**, 27,
- 24 Erectile dysfunction in the aging man: current options for treatment. *Aging Health*, **2006**, 2, 71-86
- 23 Treatment of Erectile Dysfunction in Chronic Kidney Disease. **2008**, 783-790
- 22 NHG-Standaard Erectiele disfunctie. **2009**, 1291-1313
- 21 [Erectile dysfunctions]. *Orvosi Hetilap*, **2009**, 150, 133-5 0.5
- 20 Erectile Dysfunction. **2009**, 519-526
- 19 Erectile Dysfunction. **2010**, 364-368.e1
- 18 Cardiovascular Issues in the Treatment of Erectile Dysfunction. **2011**, 179-193
- 17 NHG-Standaard Erectiele disfunctie. **2011**, 1495-1517
- 16 Geriatric Sexuality. **2014**, 377-415
- 15 Diagnostik und medikamentöse Therapie der erektilen Dysfunktion. **2014**, 1-12
- 14 Oral Prescription Therapy for Erectile Dysfunction. *Contemporary Endocrinology*, **2016**, 163-173 0.3 0
- 13 PREVENTION OF TADALAFIL INDUCED BACKACHE IN ERECTILE DYSFUNCTION PATIENTS. *Journal of Evolution of Medical and Dental Sciences*, **2016**, 5, 1410-1412 0.1

- 12 Treating Erectile Dysfunctions. **2017**, 201-225
- 11 Sex and Pharmacological Sexual Enhancement. **2017**, 387-411
- 10 Legal retirement age of sexual life in Korean men. *Korean Journal of Sexual Health*, **2020**, 4, 9-18 0.1 1
- 9 Pharmacology of Male Sexual Function. **2020**, 159-174
- 8 Acute Toxicities of Therapy: Urologic Complications. **2006**, 1435-1442
- 7 Sexual Dysfunction and Cardiovascular Risk Links and Solutions. **2009**, 199-215
- 6 Cardiac Issues Related to Erectile Dysfunction. **2006**, 61-75
- 5 Use of Stem Cells in the Treatment of Erectile Dysfunction. **2021**, 347-365
- 4 Testosterone replacement therapy and erectile dysfunction.. *International Journal of Impotence Research*, **2022**, 2.1
- 3 A preliminary study of the efficacy of the polyherbal preparation Sao Thong Tai for erectile dysfunction among elderly men: a double-blind, randomized controlled trial. *Clinical Phytoscience*, **2022**, 8, 2.4
- 2 Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study.. *Diabetology and Metabolic Syndrome*, **2022**, 14, 56 5.4
- 1 Fabric phase sorptive extraction coupled with UPLC-ESI-MS/MS method for fast and sensitive quantitation of tadalafil in a bioequivalence study. *Saudi Pharmaceutical Journal*, **2022**, 4.2